Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

被引：0
|
作者：
M. González-Cao
A. Arance
J. M. Piulats
I. Marquez-Rodas
J. L. Manzano
A. Berrocal
G. Crespo
D. Rodriguez
E. Perez-Ruiz
M. Berciano
A. Soria
A. G. Castano
E. Espinosa
C. Montagut
L. Alonso
T. Puertolas
C. Aguado
M. A. Royo
R. Blanco
J. F. Rodríguez
E. Muñoz
P. Mut
F. Barron
S. Martin-Algarra
机构：
[1] Quiron Dexeus University Hospital,Translational Cancer Research Unit, Dr. Rosell Oncology Institute
[2] Hospital Clinic I Provincial,undefined
[3] Catalan Institute of Oncology,undefined
[4] Gregorio Marañón Institute of Health Research,undefined
[5] Germans Trias I Pujol University Hospital,undefined
[6] General University Hospital,undefined
[7] Burgos University Hospital,undefined
[8] Insular University Hospital of Gran Canaria,undefined
[9] Costa del Sol Hospital,undefined
[10] Regional University Hospital of Malaga,undefined
[11] Ramony Cajal Hospital,undefined
[12] Marqués de Valdecilla University Hospital,undefined
[13] La Paz University Hospital,undefined
[14] Del Mar University Hospital,undefined
[15] Virgen de la Victoria Hospital,undefined
[16] Miguel Servet University Hospital,undefined
[17] San Carlos Hospital,undefined
[18] Dr. Peset Hospital,undefined
[19] Consorci Sanitari de Terrassa,undefined
[20] Clara Campal Hospital,undefined
[21] Valld’Hebron University Hospital,undefined
[22] Son Llatzer University Hospital,undefined
[23] National Cancer Institute,undefined
[24] Navarra University Clinic,undefined
来源：
Clinical and Translational Oncology | 2017年 / 19卷
关键词：
Expanded access program; Melanoma; Pembrolizumab; Survival; CNS metastases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：761 / 768
页数：7
相关论文
共 50 条
  • [1] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    Gonzalez-Cao, M.
    Arance, A.
    Piulats, J. M.
    Marquez-Rodas, I.
    Manzano, J. L.
    Berrocal, A.
    Crespo, G.
    Rodriguez, D.
    Perez-Ruiz, E.
    Berciano, M.
    Soria, A.
    Castano, A. G.
    Espinosa, E.
    Montagut, C.
    Alonso, L.
    Puertolas, T.
    Aguado, C.
    Royo, M. A.
    Blanco, R.
    Rodriguez, J. F.
    Munoz, E.
    Mut, P.
    Barron, F.
    Martin-Algarra, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 761 - 768
  • [2] Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program
    Berrocal, Alfonso
    Arance, Ana
    Lopez Martin, Jose Antonio
    Soriano, Virtudes
    Munoz, Eva
    Alonso, Lorenzo
    Espinosa, Enrique
    Lopez Criado, Pilar
    Valdivia, Javier
    Martin Algarra, Salvador
    MELANOMA RESEARCH, 2014, 24 (06) : 577 - 583
  • [3] Spanish experience with the ipilimumab Expanded Access Program.
    Berrocal, Alfonso
    Lopez-Martin, Jose A.
    Maria Arance, Ana
    Soriano, V.
    Espinosa, Enrique
    Lopez Criado, M. Pilar
    Munoz, Eva
    Pablo Berros, Jose
    Soria, A.
    Marquez, I.
    Sancho, P.
    Gil, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment
    Yang, C-K.
    Liu, J-H.
    Lin, C-C.
    Liu, T-C.
    Cheng, P-T.
    Lin, C-Y.
    Hu, H-T.
    Cao, C-R.
    Huang, W-T.
    Chen, L-P.
    Chang, W-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
    Wilgenhof, Sofie
    Du Four, Stephanie
    Vandenbroucke, Frederik
    Everaert, Hendrik
    Salmon, Isabelle
    Lienard, Danielle
    Del Marmol, Veronique
    Neyns, Bart
    JOURNAL OF IMMUNOTHERAPY, 2013, 36 (03) : 215 - 222
  • [6] Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
    Bisschop, Cornelis
    Wind, Thijs T.
    Blank, Christian U.
    Koornstra, Rutger H. T.
    Kapiteijn, Ellen
    Van den Eertwegh, Alfonsus J. M.
    De Groot, Jan Willem B.
    Jalving, Mathilde
    Hospers, Geke A. P.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (06) : 208 - 214
  • [7] A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP)
    Perdon, Karen Mae
    Kim, Dae Won
    Balmes, Gener C.
    VanAnh Trinh
    McIntyre, Susan E.
    Diab, Adi
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Hwu, Patrick
    James, Marihella
    Philip, Ann
    Vardeleon, Anna
    Cain, Suzanne
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Ipilimumab for advanced, refractory melanoma: A report of the Israeli cohort of expanded access program
    Shapira-Frommer, Ronnie
    Stephen, Frank
    Ben-Ami, Eytan
    Hamburger, Tamar
    Markel, Gal
    Ospovat, Inna
    Zippel, Douglas
    Merims, Sharon
    Apter, Sara
    Steinberg, Hani
    Silman-Steiberg, Yael
    Peretz, Tamar
    Lotem, Michal
    Schachter, Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC
    Majem Tarruella, M.
    Campillo, J.
    Grau Bejar, J. F.
    Carcereny, E.
    Bernabe Caro, R.
    Garcia, Y.
    Artal-Cortes, A.
    Gonzalez Cao, M.
    Lianes, P.
    Paredes Lario, A.
    Sereno Moyano, M.
    Mielgo Rubio, X.
    Macias, J. A.
    Provencio Pulla, M.
    Rodriguez-Abreu, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
12345